Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study - ScienceDirect
Available iCS plus LABA combination products | Download Table
Pharmaceuticals | Free Full-Text | Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study - ScienceDirect
Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study - ScienceDirect
GlaxoSmithKline Is Focused on Maintaining Leadership in This Segment
Farmacoutilizzazione della terapia inalatoria nella Medicina Generale italiana
FDA duyệt Trelegy (GSK), sau kết quả khả quan so sánh với combo 2 hoạt chất
American College of Chest Physicians - In a real-world setting, LAMA-LABA- ICS is as effective as LAMA-LABA to prevent COPD exacerbations, but incidence of pneumonia increased with triple therapy initiation: https://hubs.ly/H0pPLQ20 | Facebook
Effectiveness of Treatment With Dual Bronchodilation (LABA/LAMA) Compared With Combination Therapy (LABA/ICS) for Patients With COPD: A Population-Based Study | Archivos de Bronconeumología
The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study | npj Primary Care Respiratory Medicine
Population-based study of LAMA monotherapy effectiveness compared with LABA/ LAMA as initial treatment for COPD in primary care | npj Primary Care Respiratory Medicine
MEDI:GATE NEWS : GSK 트렐리지 엘립타, 성인 천식 환자 위한 3제 복합요법 치료제로 적응증 확대
Atti della Accademia Lancisiana - Numeri della Rivista
A new alphabet for COPD care | European Respiratory Society
IMPACT Study Data | TRELEGY ELLIPTA (fluticasone furoate, umeclidinium & vilanterol)
Mario Cazzola, ERS 2018 – Impact of ICS/LABA and LABA/LAMA on lung function and exacerbation of COPD - YouTube
ICS/LABA/LAMA per la BPCO è stata approvata in Europa • NCF
Toby Capstick on X: "#Trelegy Ellipta: The second ICS/LAMA/LABA inhaler in the UK, licensed for #COPD. https://t.co/NSYtv7bTYS (An alternative ICS/LABA /LAMA inhaler is available: #Trimbow MDI) https://t.co/vQBgh9lvM2" / X
LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the d | COPD
Proven mechanisms of action leading to synergistic or additive... | Download Scientific Diagram